Dissecting Alzheimer disease in Down syndrome using mouse models
Open accessThe DOI matches its Crossref record; 84 of the 84 references it cites were found in a registry or an index.
Abstract
Down syndrome (DS) is a common genetic condition caused by the presence of three copies of chromosome 21 (trisomy 21). This greatly increases the risk of Alzheimer disease (AD), but although virtually all people with DS have AD neuropathology by 40 years of age, not all develop dementia. To dissect the genetic contribution of trisomy 21 to DS phenotypes including those relevant to AD, a range of DS mouse models has been generated which are trisomic for chromosome segments syntenic to human chromosome 21. Here, we consider key characteristics of human AD in DS (AD-DS), and our current state of knowledge on related phenotypes in AD and DS mouse models. We go on to review important features needed in future models of AD-DS, to understand this type of dementia and so highlight pathogenic mechanisms relevant to all populations at risk of AD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
RETRACTED ARTICLE: A specific amyloid-β protein assembly in the brain impairs memory
Lesné, S., Koh, M. T., Kotilinek, L., Kayed, R., Glabe, C. G., Yang, A., Gallagher, M., & Ashe, K. H. (2006) · Nature · doi:10.1038/nature04533 · Cited by 2,769
RetractedNeuropathological stageing of Alzheimer-related changes.
Braak, H., & Braak, E. (1991) · Acta Neuropathologica · doi:10.1007/bf00308809 · Cited by 16,123
Neuropathological alterations in Alzheimer disease
Serrano-Pozo, A., Frosch, M. P., Masliah, E., & Hyman, B. T. (2011) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a006189 · Cited by 3,345 · cited 1×
“…and BACE1 activity (Mori et al., 2010) Mice overexpressing S100β show accelerated signs of aging (Shapiro and Whitaker-Azmitia, 2004) neuropathology (Shapiro et al., 2004) and behavioral deficits (Borella et al., 2003) S100β upregulated in DS and AD (Griffin et al., 1989; Sheng et al., 1994)…”
BackgroundIntracellular amyloid-β in Alzheimer's disease
LaFerla, F. M., Green, K. N., & Oddo, S. (2007) · Nature Reviews Neuroscience · doi:10.1038/nrn2168 · Cited by 1,942
Brain interleukin 1 and S-100 immunoreactivity are elevated in Down syndrome and Alzheimer disease.
Griffin, W. S., Stanley, L. C., Ling, C., White, L., MacLeod, V, Perrot, L. J., White, C. L., & Araoz, C. (1989) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.86.19.7611 · Cited by 1,777 · cited 1×
“…(Shapiro and Whitaker-Azmitia, 2004) neuropathology (Shapiro et al., 2004) and behavioral deficits (Borella et al., 2003) S100β upregulated in DS and AD (Griffin et al., 1989; Sheng et al., 1994) S100β overexpression positively correlates with age in DS patients (Royston et al., 1999) SOD1,…”
BackgroundTwo amyloid precursor protein transgenic mouse models with Alzheimer disease-like pathology
Sturchler-Pierrat, C., Abramowski, D., Duke, M., Wiederhold, K.-H., Mistl, C., Rothacher, S., Ledermann, B., Bürki, K., Frey, P., Paganetti, P. A., et al. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.24.13287 · Cited by 1,507
Neuronal loss correlates with but exceeds neurofibrillary tangles in Alzheimer's disease
Gómez‐Isla, T., Hollister, R., West, H., Mui, S., Growdon, J. H., Petersen, R. C., Parisi, J. E., & Hyman, B. T. (1997) · Annals of Neurology · doi:10.1002/ana.410410106 · Cited by 1,489
Single App knock-in mouse models of Alzheimer’s disease
Saito, T., Matsuba, Y., Mihira, N., Takano, J., Nilsson, P., Itohara, S., Iwata, N., & Saido, T. C. (2014) · Nature Neuroscience · doi:10.1038/nn.3697 · Cited by 1,366 · cited 1×
“For example, the recent genomically humanized NLF mouse (Saito et al., 2014), which has human amino acid residues at key sites within APP that affect its processing, may yield new insights into the biology of both AD and AD-DS, partly through expressing mutant APP at physiological levels.”
BackgroundVerret, L., Mann, E. O., Hang, G. B., Barth, A. M. I., Cobos, I., Ho, K., Devidze, N., Masliah, E., Kreitzer, A. C., Mody, I., et al. (2012) · Cell · doi:10.1016/j.cell.2012.02.046 · Cited by 1,216
Occurrence of neuropathological changes and dementia of Alzheimer’s disease in Down’s syndrome
Wisniewski, K. E., Wisniewski, H. M., & Wen, G. Y. (1985) · Annals of Neurology · doi:10.1002/ana.410170310 · Cited by 1,159 · cited 4×
“9:268. doi: 10.3389/fnbeh.2015.00268 Dissecting Alzheimer disease in Down syndrome using mouse models Xun Yu Choong1, 2, Justin L. Tosh 1, 2, Laura J. Pulford 1, 2 and Elizabeth M. C. Fisher 1, 2* 1 Department of Neurodegenerative Disease, Institute of Neurology, University College London, London, UK, 2 The LonDownS C…”
BackgroundMethodInfluentialBlalock, E. M., Geddes, J. W., Chen, K. C., Porter, N. M., Markesbery, W. R., & Landfield, P. W. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0308512100 · Cited by 1,025
Neurotoxicity of Amyloid -Protein: Synaptic and Network Dysfunction
Mucke, L., & Selkoe, D. J. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a006338 · Cited by 1,000 · cited 1×
“…activity have been characterized across numerous APP transgenic mice (Born, 2015), but it is unclear whether these phenotypes are primarily driven by amyloid overproduction (Mucke and Selkoe, 2012) or are an effect of unphysiological APP overexpression during development (Born et al., 2014).”
BackgroundChishti, M. A., Yang, D.-S., Janus, C., Phinney, A. L., Horne, P., Pearson, J., Strome, R., Zuker, N., Loukides, J., French, J., et al. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m100710200 · Cited by 955
Relationship of microglia and astrocytes to amyloid deposits of Alzheimer disease
Itagaki, S., McGeer, P. L., Akiyama, H., Zhu, S., & Selkoe, D. (1989) · Journal of Neuroimmunology · doi:10.1016/0165-5728(89)90115-x · Cited by 940
A mouse model for Down syndrome exhibits learning and behaviour deficits
Reeves, R. H., Irving, N. G., Moran, T. H., Wohn, A., Kitt, C., Sisodia, S. S., Schmidt, C., Bronson, R. T., & Davisson, M. T. (1995) · Nature Genetics · doi:10.1038/ng1095-177 · Cited by 913 · cited 1×
“However, the vast majority of studies relating to AD-DS have been performed on the Ts65Dn mouse, as this has been an extremely important “standard model” of DS for many years, prior to the development of newer strains by chromosome engineering (Davisson et al., 1993; Reeves et al., 1995; Table 2).”
BackgroundMcGeer, P. L., Itagaki, S., Tago, H., & McGeer, E. G. (1987) · Neuroscience Letters · doi:10.1016/0304-3940(87)90696-3 · Cited by 836
Webster, S. J., Bachstetter, A. D., Nelson, P. T., Schmitt, F. A., & Van Eldik, L. J. (2014) · Frontiers in Genetics · doi:10.3389/fgene.2014.00088 · Cited by 755 · cited 2×
“…is through studying mouse models, and a large number of transgenic strains have been generated to understand specific aspects of AD pathology, most of which have human gene mutations that give rise to rare early-onset familial Alzheimer disease (FAD; Braidy et al., 2012;Webster et al., 2014).”
BackgroundStreit, W. J., Braak, H., Xue, Q.-S., & Bechmann, I. (2009) · Acta Neuropathologica · doi:10.1007/s00401-009-0556-6 · Cited by 727
The genetics of Alzheimer disease
Tanzi, R. E. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a006296 · Cited by 727
Takahashi, R. H., Milner, T. A., Li, F., Nam, E. E., Edgar, M. A., Yamaguchi, H., Beal, M. F., Xu, H., Greengard, P., & Gouras, G. K. (2002) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)64463-x · Cited by 706
Epilepsy and Cognitive Impairments in Alzheimer Disease
Palop, J. J. (2009) · Archives of Neurology · doi:10.1001/archneurol.2009.15 · Cited by 684
Moechars, D., Dewachter, I., Lorent, K., Reversé, D., Baekelandt, V., Naidu, A., Tesseur, I., Spittaels, K., Haute, C. V. D., Checler, F., et al. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.10.6483 · Cited by 668
Early Aβ accumulation and progressive synaptic loss, gliosis, and tangle formation in AD brain
Ingelsson, M., Fukumoto, H., Newell, K. L., Growdon, J. H., Hedley–Whyte, E. T., Frosch, M. P., Albert, M. S., Hyman, B. T., & Irizarry, M. C. (2004) · Neurology · doi:10.1212/01.wnl.0000115115.98960.37 · Cited by 666
Sanchez, P. E., Zhu, L., Verret, L., Vossel, K. A., Orr, A. G., Cirrito, J. R., Devidze, N., Ho, K., Yu, G.-Q., Palop, J. J., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1121081109 · Cited by 638
A genetic cause of Alzheimer disease: mechanistic insights from Down syndrome
Wiseman, F. K., Al-Janabi, T., Hardy, J., Karmiloff-Smith, A., Nizetic, D., Tybulewicz, V. L. J., Fisher, E. M. C., & Strydom, A. (2015) · Nature Reviews Neuroscience · doi:10.1038/nrn3983 · Cited by 562 · cited 3×
“In-depth phenotypic studies across development with infants and adults with DS are already underway (Wiseman et al., 2015).”
BackgroundInfluentialSelf-citationGrabowski, T. J., Cho, H. S., Vonsattel, J. P. G., Rebeck, G. W., & Greenberg, S. M. (2001) · Annals of Neurology · doi:10.1002/ana.1009 · Cited by 523
Krabbe, G., Halle, A., Matyash, V., Rinnenthal, J. L., Eom, G. D., Bernhardt, U., Miller, K. R., Prokop, S., Kettenmann, H., & Heppner, F. L. (2013) · PLoS ONE · doi:10.1371/journal.pone.0060921 · Cited by 478
Mann, D. M. A., & Esiri, M. M. (1989) · Journal of the Neurological Sciences · doi:10.1016/0022-510x(89)90019-1 · Cited by 471 · cited 1×
“Alzheimer disease (AD) pathology is found in the brains of virtually all people with DS by 40 years of age (Wisniewski et al., 1985; Mann and Esiri, 1989), and trisomy 21 causes an increased risk of dementia such that approximately one third of the DS population has AD (“AD-DS”) by the age of 60,…”
BackgroundDevelopmental abnormalities and age-related neurodegeneration in a mouse model of Down syndrome
Holtzman, D. M., Santucci, D., Kilbridge, J., Chua-Couzens, J., Fontana, D. J., Daniels, S. E., Johnson, R. M., Chen, K., Sun, Y., Carlson, E., et al. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.23.13333 · Cited by 448
Astrocytes in physiological aging and Alzheimer’s disease
Rodríguez-Arellano, J. J., Parpura, V., Zorec, R., & Verkhratsky, A. (2016) · Neuroscience · doi:10.1016/j.neuroscience.2015.01.007 · Cited by 439
An Aneuploid Mouse Strain Carrying Human Chromosome 21 with down Syndrome Phenotypes.
O'Doherty, A., Ruf, S., Mulligan, C., Hildreth, V., Errington, M. L., Cooke, S., Sesay, A., Modino, S., Vanes, L., Hernandez, D., et al. (2005) · Science · doi:10.1126/science.1114535 · Cited by 434 · cited 1×
“For example, there is a wide variety of non-cognitive symptoms and behavioral changes across all four AD genotypes, including personality changes (Nelson et al., 2001; Ball et al., 2008), hallucinations (Sleegers et al., 2006; Basun et al., 2008; Guyant-Marechal et al., 2008), paranoia (Sleegers et…”
BackgroundSelf-citationKorbel, J. O., Tirosh-Wagner, T., Urban, A. E., Chen, X.-N., Kasowski, M., Dai, L., Grubert, F., Erdman, C., Gao, M. C., Lange, K., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0813248106 · Cited by 399 · cited 1×
“Dup-APP cases demonstrate that the three doses of APP arising from trisomy 21 are likely to be causative for AD-DS. Conversely, although very rare, partial trisomy 21 excluding APP (i.e., with two “doses” of APP) does not appear to lead to AD (Prasher et al., 1998; Korbel et al., 2009).”
BackgroundGrudzien, A., Shaw, P., Weintraub, S., Bigio, E., Mash, D. C., & Mesulam, M. M. (2007) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2006.02.007 · Cited by 396 · cited 1×
“In people with early AD pathology or mild cognitive impairment, neurofibrillary pathology has been detected in BFCNs (Mesulam et al., 2004; Grudzien et al., 2007), while their loss has been observed in patients with SAD (and other neurodegenerative disorders; Zarow et al., 2003).”
Cataldo, A. M., Barnett, J. L., Pieroni, C., & Nixon, R. A. (1997) · The Journal of Neuroscience · doi:10.1523/jneurosci.17-16-06142.1997 · Cited by 393
Sago, H., Carlson, E. J., Smith, D. J., Kilbridge, J., Rubin, E. M., Mobley, W. C., Epstein, C. J., & Huang, T.-T. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.11.6256 · Cited by 382 · cited 2×
“…Tybulewicz and Fisher, 2006), to provide a set of models that are segmentally trisomic for regions orthologous to Hsa21 (Davisson et al., 1993; Sago et al., 1998; Olson et al., 2004; Li et al., 2007; Herault et al., 2009; Pereira et al., 2009; Yu et al., 2010a; Liu et al., 2011, 2014; Brault…”
BackgroundCooper, J. D., Salehi, A., Delcroix, J.-D., Howe, C. L., Belichenko, P. V., Chua-Couzens, J., Kilbridge, J. F., Carlson, E. J., Epstein, C. J., & Mobley, W. C. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.181219298 · Cited by 336
Transgenic mouse models of Alzheimer’s disease.
Elder, G. A., Gama Sosa, M. A., & De Gasperi, R. (2010) · Mount Sinai Journal of Medicine A Journal of Translational and Personalized Medicine · doi:10.1002/msj.20159 · Cited by 336
Domains of genome-wide gene expression dysregulation in Down’s syndrome
Letourneau, A., Santoni, F. A., Bonilla, X., Sailani, M. R., Gonzalez, D., Kind, J., Chevalier, C., Thurman, R., Sandstrom, R. S., Hibaoui, Y., et al. (2014) · Nature · doi:10.1038/nature13200 · Cited by 319
Mouse models of Alzheimer's disease
Hall, A. M., & Roberson, E. D. (2012) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2011.11.017 · Cited by 317
A Human Stem Cell Model of Early Alzheimer’s Disease Pathology in Down Syndrome
Shi, Y., Kirwan, P., Smith, J., MacLean, G., Orkin, S. H., & Livesey, F. J. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3003771 · Cited by 310
Synaptic structural abnormalities in the Ts65Dn mouse model of down syndrome
Belichenko, P. V., Masliah, E., Kleschevnikov, A. M., Villar, A. J., Epstein, C. J., Salehi, A., & Mobley, W. C. (2004) · Journal of Comparative Neurology · doi:10.1002/cne.20337 · Cited by 297
Down syndrome and Alzheimer's disease: common pathways, common goals
Hartley, D., Blumenthal, T., Carrillo, M., DiPaolo, G., Esralew, L., Gardiner, K., Granholm, A.-C., Iqbal, K., Krams, M., Lemere, C., et al. (2015) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2014.10.007 · Cited by 290 · cited 3×
“Other triplicated genes in Ts65Dn irrelevant to DS include several genes encoding dynein light chains that may influence endosomal trafficking, and so potentially affect neuronal phenotypes (Hartley et al., 2015).”
BackgroundKimura, R., Kamino, K., Yamamoto, M., Nuripa, A., Kida, T., Kazui, H., Hashimoto, R., Tanaka, T., Kudo, T., Yamagata, H., et al. (2007) · Human Molecular Genetics · doi:10.1093/hmg/ddl437 · Cited by 281
Overexpression of Dyrk1A contributes to neurofibrillary degeneration in down syndrome
Liu, F., Liang, Z., Wegiel, J., Hwang, Y., Iqbal, K., Grundke‐Iqbal, I., Ramakrishna, N., & Gong, C. (2008) · The FASEB Journal · doi:10.1096/fj.07-104539 · Cited by 272
Cataldo, A. M., Petanceska, S., Peterhoff, C. M., Terio, N. B., Epstein, C. J., Villar, A., Carlson, E. J., Staufenbiel, M., & Nixon, R. A. (2003) · The Journal of Neuroscience · doi:10.1523/jneurosci.23-17-06788.2003 · Cited by 241
Neurological phenotypes for Down syndrome across the life span
Lott, I. T. (2012) · Progress in Brain Research · doi:10.1016/b978-0-444-54299-1.00006-6 · Cited by 225 · cited 1×
“…although this can be difficult to determine, particularly as DS has been characterized as a syndrome of accelerated aging in both clinical (Lott, 2012; Zigman, 2013) and epigenetic terms (Horvath et al., 2015), and because aging remains the clearest non-genetic risk factor for all forms…”
BackgroundDuchon, A., Raveau, M., Chevalier, C., Nalesso, V., Sharp, A. J., & Herault, Y. (2011) · Mammalian Genome · doi:10.1007/s00335-011-9356-0 · Cited by 224
Li, Z., Yu, T., Morishima, M., Pao, A., LaDuca, J., Conroy, J., Nowak, N., Matsui, S.-I., Shiraishi, I., & Yu, Y. E. (2007) · Human Molecular Genetics · doi:10.1093/hmg/ddm086 · Cited by 218
Leverenz, J. B., & Raskind, M. A. (1998) · Experimental Neurology · doi:10.1006/exnr.1997.6777 · Cited by 214
Trisomy 21 and early brain development
Haydar, T. F., & Reeves, R. H. (2012) · Trends in Neurosciences · doi:10.1016/j.tins.2011.11.001 · Cited by 200 · cited 1×
“Similarly, phenotypes observed in DS mice may be influenced by genetic background (O’Doherty et al., 2005; Galante et al., 2009; Costa et al., 2010; Deitz and Roper, 2011; Haydar and Reeves, 2012).”
BackgroundKim, W. S., Rahmanto, A. S., Kamili, A., Rye, K.-A., Guillemin, G. J., Gelissen, I. C., Jessup, W., Hill, A. F., & Garner, B. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m607831200 · Cited by 191 · cited 2×
“…2005; Mok et al., 2014) ABCG1 ABCG1 overexpression stimulates cholesterol efflux in vitro (Kim et al., 2007; Tansley et al., 2007) and either reduces (Kim et al., 2007) or increases Aβ production (Tansley et al., 2007), the latter through an increase in APP processing ABCG1 gene upregulated in…”
BackgroundMolecular characterization of the translocation breakpoints in the down syndrome mouse model Ts65Dn
Reinholdt, L. G., Ding, Y., Gilbert, G. T., Czechanski, A., Solzak, J. P., Roper, R. J., Johnson, M. T., Donahue, L. R., Lutz, C., & Davisson, M. T. (2011) · Mammalian Genome · doi:10.1007/s00335-011-9357-z · Cited by 186
Born, H. A., Kim, J.-Y., Savjani, R. R., Das, P., Dabaghian, Y. A., Guo, Q., Yoo, J. W., Schuler, D. R., Cirrito, J. R., Zheng, H., et al. (2014) · The Journal of Neuroscience · doi:10.1523/jneurosci.5171-13.2014 · Cited by 178 · cited 1×
“…activity have been characterized across numerous APP transgenic mice (Born, 2015), but it is unclear whether these phenotypes are primarily driven by amyloid overproduction (Mucke and Selkoe, 2012) or are an effect of unphysiological APP overexpression during development (Born et al., 2014).”
BackgroundCorrelating familial Alzheimer’s disease gene mutations with clinical phenotype
Ryan, N. S., & Rossor, M. N. (2010) · Biomarkers in Medicine · doi:10.2217/bmm.09.92 · Cited by 176
Voronov, S. V., Frere, S. G., Giovedi, S., Pollina, E. A., Borel, C., Zhang, H., Schmidt, C., Akeson, E. C., Wenk, M. R., Cimasoni, L., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0803756105 · Cited by 174
Perez-Cruz, C., Nolte, M. W., van Gaalen, M. M., Rustay, N. R., Termont, A., Tanghe, A., Kirchhoff, F., & Ebert, U. (2011) · The Journal of Neuroscience · doi:10.1523/jneurosci.6142-10.2011 · Cited by 172
Cholinergic Changes in the APP23 Transgenic Mouse Model of Cerebral Amyloidosis
Boncristiano, S., Calhoun, M. E., Kelly, P. H., Pfeifer, M., Bondolfi, L., Stalder, M., Phinney, A. L., Abramowski, D., Sturchler-Pierrat, C., Enz, A., et al. (2002) · The Journal of Neuroscience · doi:10.1523/jneurosci.22-08-03234.2002 · Cited by 160
Kumar-Singh, S. (2000) · Human Molecular Genetics · doi:10.1093/hmg/9.18.2589 · Cited by 158
Carlson, G. A., Borchelt, D. R., Dake, A., Turner, S., Danielson, V., Coffin, J. D., Eckman, C., Meiners, J., Nilsen, S. P., Younkin, S. G., et al. (1997) · Human Molecular Genetics · doi:10.1093/hmg/6.11.1951 · Cited by 158
Margallo‐Lana, M. L., Moore, P. B., Kay, D. W. K., Perry, R. H., Reid, B. E., Berney, T. P., & Tyrer, S. P. (2007) · Journal of Intellectual Disability Research · doi:10.1111/j.1365-2788.2006.00902.x · Cited by 145
Communication breaks-Down: From neurodevelopment defects to cognitive disabilities in Down syndrome
Contestabile, A., Benfenati, F., & Gasparini, L. (2010) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2010.01.003 · Cited by 134 · cited 1×
“To study mouse models of AD-DS, it is critical to dissect neurodevelopmental from neurodegenerative effects (Bothwell and Giniger, 2000; Contestabile et al., 2010).”
BackgroundYu, T., Liu, C., Belichenko, P., Clapcote, S. J., Li, S., Pao, A., Kleschevnikov, A., Bechard, A. R., Asrar, S., Chen, R., et al. (2010) · Brain Research · doi:10.1016/j.brainres.2010.09.107 · Cited by 127 · cited 3×
“The Dp1(16)Yey;Dp1(17)Yey;Dp1(10)Yey (or Ts1Yey;Ts3Yey;Ts2Yey) mouse was generated by crossing together three partial trisomy models (Yu et al., 2010a) and spans the entirety of the Hsa21-syntenic regions.”
BackgroundMethodBasun, H., Bogdanovic, N., Ingelsson, M., Almkvist, O., Näslund, J., Axelman, K., Bird, T. D., Nochlin, D., Schellenberg, G. D., Wahlund, L.-O., et al. (2008) · Archives of Neurology · doi:10.1001/archneur.65.4.499 · Cited by 115 · cited 1×
“…changes across all four AD genotypes, including personality changes (Nelson et al., 2001; Ball et al., 2008), hallucinations (Sleegers et al., 2006; Basun et al., 2008; Guyant-Marechal et al., 2008), paranoia (Sleegers et al., 2006; Pilotto et al., 2013), and delusions (Burns et al., 1990), some…”
BackgroundStargardt, A., Swaab, D. F., & Bossers, K. (2015) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2014.08.014 · Cited by 109
Gribble, S. M., Wiseman, F. K., Clayton, S., Prigmore, E., Langley, E., Yang, F., Maguire, S., Fu, B., Rajan, D., Sheppard, O., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0060482 · Cited by 102 · cited 2×
“The Tc1 mouse is the only model which carries Hsa21, though genomic rearrangements and deletions (indicated by breaks in the chromosome) mean the mouse is functionally trisomic for only ∼75% of Hsa21 genes (Gribble et al., 2013).”
BackgroundSelf-citationNeuroinflammation in Alzheimer’s disease wanes with age
Hoozemans, J. J., Rozemuller, A. J., van Haastert, E. S., Eikelenboom, P., & van Gool, W. A. (2011) · Journal of Neuroinflammation · doi:10.1186/1742-2094-8-171 · Cited by 100
ets-2 Promotes the Activation of a Mitochondrial Death Pathway in Down's Syndrome Neurons
Helguera, P., Pelsman, A., Pigino, G., Wolvetang, E., Head, E., & Busciglio, J. (2005) · The Journal of Neuroscience · doi:10.1523/jneurosci.5107-04.2005 · Cited by 88
Role of common and rare APP DNA sequence variants in Alzheimer disease
Hooli, B. V., Mohapatra, G., Mattheisen, M., Parrado, A. R., Roehr, J. T., Shen, Y., Gusella, J. F., Moir, R., Saunders, A. J., Lange, C., et al. (2012) · Neurology · doi:10.1212/wnl.0b013e3182515972 · Cited by 87
Siarey, R. J., Kline‐Burgess, A., Cho, M., Balbo, A., Best, T. K., Harashima, C., Klann, E., & Galdzicki, Z. (2006) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2006.03971.x · Cited by 86
Choi, J. H. K., Berger, J. D., Mazzella, M. J., Morales‐Corraliza, J., Cataldo, A. M., Nixon, R. A., Ginsberg, S. D., Levy, E., & Mathews, P. M. (2009) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2009.06277.x · Cited by 83
APP transgenic mice: their use and limitations
Balducci, C., & Forloni, G. (2011) · NeuroMolecular Medicine · doi:10.1007/s12017-010-8141-7 · Cited by 79 · cited 1×
“…sites in the genome and may be driven by artificial promoters (see examples in Table 4), which vary in terms of their spatial and temporal expression patterns, and result in expression at often 5–10 fold compared to endogenous mouse orthologue (Balducci and Forloni, 2011; Hall and Roberson, 2012).”
BackgroundMurray, A., Letourneau, A., Canzonetta, C., Stathaki, E., Gimelli, S., Sloan-Bena, F., Abrehart, R., Goh, P., Lim, S., Baldo, C., et al. (2015) · Stem Cells · doi:10.1002/stem.1968 · Cited by 78
Sorting Nexin 27 Regulates Aβ Production through Modulating γ-Secretase Activity
Wang, X., Huang, T., Zhao, Y., Zheng, Q., Thompson, R. C., Bu, G., Zhang, Y.-W., Hong, W., & Xu, H. (2014) · Cell Reports · doi:10.1016/j.celrep.2014.09.037 · Cited by 77
Di Domenico, F., Pupo, G., Mancuso, C., Barone, E., Paolini, F., Arena, A., Blarzino, C., Schmitt, F. A., Head, E., Butterfield, D. A., et al. (2015) · Journal of Alzheimer’s Disease · doi:10.3233/jad-141254 · Cited by 75
Peacock, M. L., Warren, J. T., Roses, A. D., & Fink, J. K. (1993) · Neurology · doi:10.1212/wnl.43.6.1254 · Cited by 66
Synaptophysin and Synaptojanin-1 in Down Syndrome are Differentially Affected by Alzheimer's Disease
Martin, S. B., Dowling, A. L. S., Lianekhammy, J., Lott, I. T., Doran, E., Murphy, M. P., Beckett, T. L., Schmitt, F. A., & Head, E. (2014) · Journal of Alzheimer's Disease · doi:10.3233/jad-140795 · Cited by 64
OLIG2 over-expression impairs proliferation of human Down syndrome neural progenitors
Lu, J., Lian, G., Zhou, H., Esposito, G., Steardo, L., Delli-Bovi, L. C., Hecht, J. L., Lu, Q. R., & Sheen, V. (2012) · Human Molecular Genetics · doi:10.1093/hmg/dds052 · Cited by 63
Park, J., Yang, E. J., Yoon, J. H., & Chung, K. C. (2007) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2007.07.007 · Cited by 61
Treating enhanced GABAergic inhibition in Down syndrome: Use of GABA α5-selective inverse agonists
Martínez-Cué, C., Delatour, B., & Potier, M.-C. (2014) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2013.12.008 · Cited by 58
Haas, M. A., Bell, D., Slender, A., Lana-Elola, E., Watson-Scales, S., Fisher, E. M. C., Tybulewicz, V. L. J., & Guillemot, F. (2013) · PLoS ONE · doi:10.1371/journal.pone.0078561 · Cited by 48
Self-citationPolymorphisms in BACE2 may affect the age of onset Alzheimer's dementia in Down syndrome
Mok, K. Y., Jones, E. L., Hanney, M., Harold, D., Sims, R., Williams, J., Ballard, C., & Hardy, J. (2014) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2013.12.022 · Cited by 48
Clinical, biological, and imaging features of monogenic Alzheimer’s disease
Pilotto, A., Padovani, A., & Borroni, B. (2013) · BioMed Research International · doi:10.1155/2013/689591 · Cited by 47
Altered Distribution of Hippocampal Interneurons in the Murine down Syndrome Model Ts65Dn.
Hernández-González, S., Ballestín, R., López-Hidalgo, R., Gilabert-Juan, J., Blasco-Ibáñez, J. M., Crespo, C., Nácher, J., & Varea, E. (2015) · Neurochemical Research · doi:10.1007/s11064-014-1479-8 · Cited by 41
Cheon, M. S., Bajo, M., Kim, S. H., Claudio, J. O., Stewart, A. K., Patterson, D., Kruger, W. D., Kondoh, H., & Lubec, G. (2003) · Amino Acids · doi:10.1007/s00726-002-0337-1 · Cited by 35
Cited by
Dementia in Down syndrome: unique insights for Alzheimer disease research
Lott, I. T., & Head, E. (2019) · Nature Reviews Neurology · doi:10.1038/s41582-018-0132-6 · Cited by 383
Jin, M., Xu, R., Wang, L., Alam, M. M., Ma, Z., Zhu, S., Martini, A. C., Jadali, A., Bernabucci, M., Xie, P., et al. (2022) · Cell Stem Cell · doi:10.1016/j.stem.2022.06.007 · Cited by 174
Colacurcio, D. J., Pensalfini, A., Jiang, Y., & Nixon, R. A. (2018) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2017.10.001 · Cited by 167
Kazuki, Y., Gao, F. J., Li, Y., Moyer, A. J., Devenney, B., Hiramatsu, K., Miyagawa-Tomita, S., Abe, S., Kazuki, K., Kajitani, N., et al. (2020) · eLife · doi:10.7554/elife.56223 · Cited by 125
A review of the mechanisms underlying selected comorbidities in Alzheimer’s disease
Maciejewska, K., Czarnecka, K., & Szymański, P. (2021) · Pharmacological Reports · doi:10.1007/s43440-021-00293-5 · Cited by 64
Metadata
- Authors
- Choong, X. Y., Tosh, J. L., Pulford, L. J., & Fisher, E. M. C.
- Venue
- Frontiers in Behavioral Neuroscience
- Publisher
- Frontiers Media SA
- Published
- 2015-10-13
- Volume
- 9
- Pages
- 268-268
- ISSN
- 1662-5153 (ISSN-L)
- OpenAlex
- W2183296633
- Cited by
- 42
- References
- 84
- FWCI
- 5.18
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.